Making Notable Strides in Site Engagement in a COVID-19 Era: A Look beyond IMs and SIVs

Available on Demand

As COVID-19 unmanageably accelerates, so does the rate of disruption for clinical trial operations and the risk of increased protocol deviations. Drug development executives continue to be plagued with finding new means of sustaining site engagement, enhancing site training, and maintaining data quality throughout the life cycle of the trial. Methods must be employed to avoid communicative breakdowns between the site and the sponsor and elevate this partnership amidst COVID-inflicted restrictions. This webinar will engage in thorough discussions on optimizing and revolutionizing trial models to meet timelines and create cohesiveness amongst all players: the site, the sponsor, the CRO and the investigator.

Learning Objectives:

• Leveraging technologies to enhance site engagement and ongoing site training
• Analyzing common pitfalls in the sponsor/site relationship and identifying the solutions
• Post-Crisis Review: How will this pandemic shape the future of IMs and SIVs?

Speakers:
Dr. Michael Ropacki, Vice President of Clinical and Product Development and US Site Head, Oryzon Genomics

Sebella Miller, Senior Director, Head, Clinical Operations — US, BristolMyersSquibb

Mark Surles, CEO, ScienceMedia